slides · global inventory
Problem Agitate Solution
Arc collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 26,550
Current window 22,351-22,380
Pages 885
Rows per page 30
Arc
22,351-22,380 of 26,550
25
Includes a blackbox warning text block as a competitive/safety barrier context.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
07
The slide uses a combination of a biological process diagram and a pharmacokinetic line chart to demonstrate drug synergy.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
08
The chart uses hazard ratio as a metric for efficacy in an iPSC model derived from ALS patients.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
09
The chart highlights a 'Synchronized concentration peak' at 5 hours for both PrimeC components.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
10
Includes study design parameters (NST002) and key clinical outcomes.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
11
Includes details on screen failures and misdiagnosis exclusions.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
12
The slide uses a numbered list format to categorize clinical trial endpoints.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
13
The slide defines the statistical populations used for the clinical trial results.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
14
NeuroSense Therapeutics | Investor Presentation Deck | 33 slidesNeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
15
Shows balanced enrollment across key metrics like age, BMI, and disease severity (ALSFRS-R).NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
16
The slide highlights clinical trial safety data for PrimeC.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Before After1 hit
17
The slide highlights a 37.4% reduction in disease progression with statistical significance (p=0.03) in the per-protocol population, while noting a 29% reduction in the ITT analysis.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Before After1 hit
18
The slide uses a list of icons to anchor the clinical impact of the ALSFRS-R scale.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
19
The chart visualizes the reduction in points lost, highlighting a 3.22 point difference (p=0.03).NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
20
The slide uses a human body diagram to categorize ALS symptoms and bar charts to show the reduction in point loss (slower disease progression) for each category.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
21
The chart highlights a 17.2% attenuation in the decline of SVC score for the PrimeC group compared to placebo.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
22
The slide highlights the PARADIGM trial's research pillars, including proteomics, microRNA, exosomes, and neurofilaments, in partnership with institutions like MGH and Harvard.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
23
The slide uses a 'Case Study' to validate the company's own strategy of combination therapy.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
24
NeuroSense Therapeutics | Investor Presentation Deck | 33 slidesNeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
29
The slide uses a chevron-based timeline to distinguish between past achievements (checkmarks) and future goals (dots).NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
30
This is the final slide of the deck.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
01
SiriusXM | Investor Presentation Deck | 16 slidesSiriusXM | Investor Presentation Deck | 16 slides · SiriusXM
Conference presentation Investor relations Beat · Setup1 hit
02
SiriusXM | Investor Presentation Deck | 16 slidesSiriusXM | Investor Presentation Deck | 16 slides · SiriusXM
Conference presentation Investor relations Beat · Setup1 hit
03
SiriusXM | Investor Presentation Deck | 16 slidesSiriusXM | Investor Presentation Deck | 16 slides · SiriusXM
Conference presentation Investor relations Beat · Setup1 hit
04
SiriusXM | Investor Presentation Deck | 16 slidesSiriusXM | Investor Presentation Deck | 16 slides · SiriusXM
Conference presentation Investor relations Beat · Setup1 hit
05
The chart uses a rebased share price starting at $0.10.SiriusXM | Investor Presentation Deck | 16 slides · SiriusXM
Conference presentation Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
06
SiriusXM | Investor Presentation Deck | 16 slidesSiriusXM | Investor Presentation Deck | 16 slides · SiriusXM
Conference presentation Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
07
Describes a corporate restructuring involving a split-off and subsequent acquisition.SiriusXM | Investor Presentation Deck | 16 slides · SiriusXM
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
08
Uses a before-after-bridge framework to illustrate corporate restructuring.SiriusXM | Investor Presentation Deck | 16 slides · SiriusXM
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Before After1 hit
09
The slide uses a 5-column grid layout to present strategic pillars paired with supporting evidence.SiriusXM | Investor Presentation Deck | 16 slides · SiriusXM
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit